Cortechs.ai’s NeuroQuant PET can automatically quantify amyloid PET uptake, generate SUVR and Centiloid measurements and send structured results into imaging workflows.
Aqua Medical has treated the second US patient in RESTORE-1, a 20-person IDE study evaluating whether RF vapor ablation of proximal intestinal mucosa can improve HbA1c.
A peer-reviewed NSCLC study found mature tertiary lymphoid structures in 47% of Aliya PEF-treated tumors versus 24% of controls, an exploratory signal that now needs clinical validation.
ImpediMed’s new FDA clearance adds sarcopenia risk assessment to the SOZO platform, potentially allowing muscle-loss monitoring alongside existing fluid and body-composition measurements.
Hyperfine’s newest FDA-cleared Optive AI software adds isotropic T1 imaging, stronger noise correction and workflow changes to its portable ultra-low-field Swoop MRI system.
C2N Diagnostics’ FDA-cleared PrecivityAD2 combines amyloid and tau measurements in a mass-spectrometry test intended to aid assessment of symptomatic adults aged 40 and older.
Empatica can now bring PKG-derived Parkinson’s measures into its wearable ecosystem after FDA clearance of a platform designed for continuous symptom monitoring.
ZEISS CLINIC 360 can consolidate ophthalmic images, diagnostic information and glaucoma progression analysis in a browser-based Class II medical device.
FDA Premarket Approval gives Implantica a US launch pathway for RefluxStop after long-term clinical evidence tested an implant that avoids encircling the esophagus.
UroGen Pharma will invest up to $7 million in IntraGel while securing an option on TumoCure and potential rights to three additional SRGel oncology programmes.